PARP Inhibitor's Approval Could Expand to Include Ovarian Cancer Patients Without BRCA Mutation

Phase 3 studies are giving investigators hope that Lynparza (olaparib) will gain FDA approval for the treatment of ovarian cancer, according to Ursula A. Matulonis. 
New phase 3 studies are giving investigators hope that Lynparza (olaparib) will gain FDA approval in ovarian cancer, Ursula A. Matulonis, medical director of Gynecologic Oncology at Dana-Farber Cancer Institute, says.

Lynparza was approved in December 2014 for the treatment of women with BRCA-positive advanced ovarian cancer following treatment with three or more prior lines of chemotherapy.

“With the underlying identification of BRCA mutations and maybe expanding beyond BRCA, PARP inhibitors, for sure, are the next personalized medicine for ovarian cancer," says Matulonis.

Matulonis says that the landscape of PARP inhibitors in ovarian cancer is currently changing. This modification stems from genetic testing in women for risks of developing ovarian cancer, as well as identifying different mutations within the disease.

In an interview with CURE during the 2016 Society of Gynecologic Oncology Annual Meeting, Matulonis discusses ongoing developments with Lynparza, as well as the overall future of PARP inhibitors in ovarian cancer.

Can you tell us about the phase 2 study of cediranib and Lynparza versus Lynparza alone?

That trial looked at single-agent Lynparza versus the combination of cediranib and Lynparza. Cediranib is an oral VEGF inhibitor that inhibits VEGFR-1, -2, and -3, and Lynparza is an oral PARP inhibitor. One of my junior colleagues and I showed that the median progression-free survival was longer for women receiving the combination versus the single agent. The PFS benefit was most notable in patients who did not have an underlying BRCA mutation. For those patients who had a germline BRCA mutation, the combination was fairly equivalent to single-agent Lynparza.

The interesting thing now is that this combination is moving into two phase 3 studies—those being NRG-GY004 (NCT02446600) and NRG-GY005 (NCT02502266)—which have just opened as of February 2016.

What are the hopes for NRG-GY004 and NRG-GY005?

Both of these studies are looking at this combination. NRG-GY004 is looking at platinum-sensitive recurrent ovarian cancer, and NRG-GY005 is looking at the combination in platinum-resistant ovarian cancer.

The hope is that for the sensitive patients, the combination will be either similar or superior to platinum-based chemotherapy. Investigators have a choice as to which doublet they want to use—whether they want carboplatin plus Abraxane (paclitaxel), carboplatin plus Gemzar (gemcitabine), or carboplatin plus Adriamycin (liposomal doxorubicin).

In NRG-GY005, the hope is that the combination will do better than single-agent chemotherapy. The purpose of these trials is to test this concept in patients with platinum-resistant cancer, and also patients with platinum-sensitive cancer. It's really a different type of patient and a different subset of patients that we are testing this with.

Could Lynparza move to earlier lines of treatment for ovarian cancer?

There's a chance that it may, but it is unlikely for that to happen based on data from these two trials.

These two randomized phase 3 studies are really in all patients, irrespective of underlying BRCA status. Patients are being stratified for BRCA, but it's also for patients who have wild-type BRCA as well, whereas the FDA approval is really for patients who have germline BRCA-positive ovarian cancer.

Talk about this article with other patients, caregivers, and advocates in the Ovarian Cancer CURE discussion group.
CURE wants to hear from you! We are inviting you to Share Your Story with the readers of CURE. Submit your personal experience with cancer by visiting Share Your Story
Not yet receiving CURE in your mailbox? Sign up to receive CURE Magazine by visiting